China Medical System (867.HK) Received Again the “Best Pharmaceutical and Medical Company” in Golden Hong Kong Stocks Award

Company News

On January 11, the 6th Golden Hong Kong Stocks Awards Ceremony was grandly held in Crowne Plaza Shenzhen Nanshan. China Medical System Holdings Limited (“CMS”) was honored to receive again the “Best Pharmaceutical and Medical Company” in Golden Hong Kong Stocks Award. This is the 6th consecutive time that the Group won the relevant award.

Co-sponsored by Zhitong Caijing and RoyalFlush, the Golden Hong Kong Stocks Awards evaluates and ranks companies based on the following aspects: performance of the past year, industry ranking, corporate governance, business model, market influence and performance in capital market. The “Best Pharmaceutical and Medical Company” award aims to recognize the pharmaceutical and medical Hong Kong listed companies that have a healthy corporate governance structure, prominent industry position, well-developed main business and are capable to provide investors with continuous and stable return. Receiving this award again fully reflects the affirmation from the industry and capital market of the Group’s performance and growth potential.

In the past year, with the continuous deepening of the reform in China pharmaceutical industry, CMS proactively strived for changes, and continuously made new breakthroughs via innovating and progressing. In China, the NDAs of 3 innovative medicines were accepted, the registration trials of 2 innovative medicines obtained positive results, the IND applications of 3 innovative medicines were approved, and a new model of industrial investment in Chinese Biotech was launched to continuously expand the Groups innovative pipeline and rapidly empower the launching of Chinese innovative products. While achieving in-depth development in the pharmaceutical business, the Group actively integrated its internal and external resources to expand its business boundary, and entered into new business fields such as the medical aesthetics field, laying a solid foundation for its the long-term development. In addition, to actively fulfill its social responsibilities, the Group continually pays attention to public welfare and environmental protection, to contribute to society with its ordinary practices.

In the future, CMS will continue to enhance its comprehensive strength and dedicate itself to “Offering Competitive Products and Services to Meet China’s Unmet Needs for Medical Care, Health and Beauty”. While maintaining steady business performance, the Group will continue to strive for new achievements and breakthroughs!